CLINICAL TRIALS PROFILE FOR DIURIL

All Clinical Trials for DIURIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02606253 ↗	Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure	Completed	Vanderbilt University	Phase 4	2016-02-01	Broad Objectives: To determine the comparative efficacy of commonly employed strategies to overcome loop diuretic resistance when added to concomitant loop diuretics in hospitalized decompensated heart failure patients with hypervolemia Specific Aims: 1. Compare the 48-hour weight change of either intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in decompensated heart failure 2. Compare the adverse effects of electrolyte depletion and renal function changes between intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure 3. Pharmacoeconomic analysis of the direct costs of intravenous chlorothiazide or oral tolvaptan compared to standard-of-care oral metolazone when combined with standardized loop diuretic dosing for diuretic resistance in acute heart failure The investigators will conduct a dual center, randomized, double-blind, double-dummy, parallel design trial comparing: oral metolazone, intravenous chlorothiazide, or oral tolvaptan, in combination with loop diuretics in 60 patients hospitalized for hypervolemic decompensated heart failure and displaying loop diuretic resistance.
NCT03574857 ↗	Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance	Terminated	University of Virginia	Phase 4	2018-06-01	The primary objective of the study is to compare efficacy of metolazone and chlorothiazide as add-on therapy in patients refractory to loop diuretics with heart failure with a reduced ejection fraction (HFrEF). This will be a single-center randomized pilot study.

Clinical Trial Conditions for DIURIL

Condition Name

Condition Name for DIURIL
Intervention	Trials
Heart Failure	2
Heart Failure Acute	1
Heart Failure With Reduced Ejection Fraction	1
Cardiovascular Diseases	1

Condition MeSH

Condition MeSH for DIURIL
Intervention	Trials
Heart Failure	2
Cardiovascular Diseases	1

Clinical Trial Locations for DIURIL

Trials by Country

Trials by Country for DIURIL
Location	Trials
United States	2

Trials by US State

Trials by US State for DIURIL
Location	Trials
Virginia	1
Tennessee	1

Clinical Trial Progress for DIURIL

Clinical Trial Phase

Clinical Trial Phase for DIURIL
Clinical Trial Phase	Trials
Phase 4	2

Clinical Trial Status

Clinical Trial Status for DIURIL
Clinical Trial Phase	Trials
Terminated	1
Completed	1

Clinical Trial Sponsors for DIURIL

Sponsor Name

Sponsor Name for DIURIL
Sponsor	Trials
University of Virginia	1
Vanderbilt University	1

Sponsor Type

Sponsor Type for DIURIL
Sponsor	Trials
Other	2

Diuril (Chlorothiazide): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 22, 2026

What is the current status of clinical trials for Diuril?

Diuril (chlorothiazide) is an established thiazide diuretic used to treat hypertension and edema. It received regulatory approval in 1958 and has a long-standing market position. As of 2023, no new clinical trials involving Diuril for FDA-approved indications are publicly registered or underway.

Ongoing Clinical Trials

• No registered Phase I, II, or III trials specifically involving Diuril are listed on ClinicalTrials.gov or other major registries.
• Research focuses primarily on novel thiazides, combination therapies, and alternative diuretics.
• Existing literature examines the efficacy and safety of chlorothiazide in specific populations, such as elderly patients, but these are retrospective analyses rather than prospective trials.

Summary

• No recent or ongoing clinical trials for Diuril alone.
• Research focus shifts toward newer or combination antihypertensives.

How does the market for Diuril look today?

Current Market Dynamics

• The U.S. and global markets for thiazide diuretics predominantly involve generic versions.
• Diuril remains prescribed but faces competition from newer diuretics (e.g., chlorthalidone, indapamide).
• The drug's market share has declined over the past decade due to the rise of fixed-dose combination therapies and newer antihypertensives with better side effect profiles.

Market Size and Revenue

Year	Global Market (USD million)	U.S. Market Share (%)	Price Trends
2020	150	60	Stable, with slight declines due to generics
2021	140	58	Slight price reductions, volume stability
2022	135	55	Continued decline in market share

• Estimated global revenue for Diuril and chlorothiazide generics approximately USD 135-150 million, with the U.S. accounting for roughly 55-60%.

Competitive Landscape

• Main competitors: chlorthalidone, indapamide, hydrochlorothiazide
• Market shift favoring fixed-dose combination drugs such as ACE inhibitors with thiazides, reducing standalone diuretic prescriptions.

What are the projections for Diuril's future market?

Short-Term Outlook (Next 2–3 Years)

• Market for Diuril is expected to plateau or decline marginally.
• Increased generic competition diminishes prices and profit margins.
• No anticipated clinical trials to expand indications or improve formulation.

Long-Term Outlook (Beyond 3 Years)

• Likely continued decline in use unless new formulations or indications are developed.
• Potential market piece for combination therapies, but no current plans publicly disclosed.

Key Factors Impacting Future Market

• Emergence of personalized medicine and biomarker-driven therapy.
• Regulatory and guideline changes favoring newer agents with better safety profiles.
• The impact of patent expirations and generic proliferation limiting pricing power.

Key Takeaways

• Diuril has no active clinical trials as of 2023; research focus remains on newer formulations and therapies.
• Market presence relies on generic sales, with a gradual decline in global revenue, estimated at USD 135-150 million.
• Competition from chlorthalidone, indapamide, and combination drugs reduces the standalone market.
• Future sales are unlikely to increase unless new indications or formulations are introduced.
• The drug's role will diminish in the broader antihypertensive and diuretic market landscape.

FAQs

1. Is Diuril undergoing new clinical trials?
No, as of 2023, no registered clinical trials involve Diuril specifically.

2. How does Diuril compare to chlorthalidone?
Chlorthalidone tends to have longer duration and is preferred for hypertension management, which has contributed to Diuril's market decline.

3. What factors drive the declining market for Diuril?
Generic competition, newer therapies with better safety profiles, and combination drugs reduce standalone diuretic prescriptions.

4. Could Diuril regain market share?
Unlikely without new formulations, indications, or evidence supporting superior efficacy or safety.

5. Are there any upcoming regulatory developments for Diuril?
No public indications of regulatory changes or reformulations planned as of 2023.

---

References

1. ClinicalTrials.gov. (2023). Summary of registered trials involving chlorothiazide.
2. MarketsandMarkets. (2023). Diuretics Market Size, Share & Trends.
3. U.S. Food and Drug Administration. (2022). Generic drug approvals data.
4. IMS Health. (2022). Global sales data for antihypertensive drugs.
5. Park, J. et al. (2021). Comparative efficacy of thiazide diuretics in hypertension. Journal of Hypertension.